With USPTO Re-Exam Over, ExonHit and Jivan Likely to Resume Splice-Array Litigation

ExonHit said the conclusion of the reexamination paves the way for the resumption of the case between the two firms, both of which sell splice variant arrays and services.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.